Further investigations revealed that estrogen signaling disruption, such as siRNA targeting ERα, could trigger epigenetic silencing (hypermethylation) of the ZNF217 gene and that the methylation status at the ZNF217 locus was higher in ERα-negative (ER-) versus ER+ breast tumors [24]. The gene discussed is ESR1; the disease is breast neoplasm.